BEB Holdings, LLC 4

What Happened Evan Burnam, Chief Executive Officer of Turn Therapeutics (TTRX), received a grant of 160,000 derivative awards (options) on April 1, 2026. The Form 4 reports the acquisition price as $0.00 because this is an option/award rather than an open-market purchase; no immediate cash transaction or sale occurred. This is a compensation award, not an outright stock purchase or sale.

Key Details

• Transaction date: 2026-04-01 (Form 4 filed 2026-04-03).
• Transaction type/code: Grant / Award (A) — derivative option award.
• Amount: 160,000 shares (options) acquired; reported acquisition price $0.00.
• Vesting (from footnote F1): 25% vests on the first anniversary of the grant; the remaining 75% vests ratably over the next 36 months, subject to continued employment and the Issuer’s 2025 Omnibus Incentive Plan.
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Filing appears timely (transaction 4/1/2026; Form 4 filed 4/3/2026).
• Exercise price and other award terms beyond vesting are not detailed in the summary.

Context This was an option grant as part of executive compensation. Option grants vest over time and do not represent immediate ownership of marketable shares until vested and exercised, so they are not the same as an open-market purchase or sale. Such awards are routine for executives and reflect compensation/retention structure rather than a direct public-market bet by the insider.